A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo
- 1Mahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth University (Deemed to-be University), Puducherry, India
- 2Department of Pathology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth University (Deemed to-be University), Puducherry, India
- 3Department of Pharmacy, National University of Singapore, Singapore, Singapore
- 4Department of Visual Neurosciences, Singapore Eye Research Institute, Singapore, Singapore
- 5Eye-APC, Duke-NUS Medical School, Singapore, Singapore
- 6Department of General Paediatrics, Haematology/Oncology, University Children’s Hospital Tübingen, Tübingen, Germany
- 7ScirosBio (FZC), SRTI Park, Sharjah, United Arab Emirates
- 8Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
- 9Department of Ageing Research, Manipal School of Life Sciences, MAHE, Manipal, Karnataka, India
A Corrigendum on
A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo
by Kuduvalli SS, Daisy PS, Vaithy A, Purushothaman M, Ramachandran Muralidharan A, Agiesh KB, Mezger M, Antony JS, Subramani M, Dubashi B, Biswas I, Guruprasad KP and Anitha TS (2023). Front. Pharmacol. 14:1096614. doi: 10.3389/fphar.2023.1096614
In the published article, there was an error in Table 1. The values of drug doses were inadvertently misrepresented during the final assembly of Table 1. The corrected Table 1 and its caption appear below.
TABLE 1. The concentration of each drug used in the treatment of animals both individually and in combination.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: glioma, metformin, epigallocatechin gallate (EGCG), molecular docking, quantum mechanics (QM), ROS-reactive oxygen species, PI3K/Akt/mTOR pathway
Citation: Kuduvalli SS, Daisy PS, Vaithy A, Purushothaman M, Muralidharan AR, Agiesh KB, Mezger M, Antony JS, Subramani M, Dubashi B, Biswas I, Guruprasad KP and Anitha TS (2024) Corrigendum: A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo. Front. Pharmacol. 14:1322332. doi: 10.3389/fphar.2023.1322332
Received: 16 October 2023; Accepted: 22 December 2023;
Published: 09 January 2024.
Edited by:
Jianqiang Xu, Dalian University of Technology, ChinaReviewed by:
Chandrabose Selvaraj, Alagappa University, IndiaCopyright © 2024 Kuduvalli, Daisy, Vaithy, Purushothaman, Muralidharan, Agiesh, Mezger, Antony, Subramani, Dubashi, Biswas, Guruprasad and Anitha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: T. S. Anitha, dHNhbml0aGE2QHBvbmRpdW5pLmFjLmlu
†Present address: T. S. Anitha, Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, India